In recent years, there have been significant advancements in cancer treatment, particularly with the use of Monoclonal Antibodies (mAbs). These targeted therapies shown promise managing different types fewer side effects due to their high specificity. They become a predominant category newly developed drugs. antibodies offer diverse mechanisms action and can directly target cells while also boo...

INTRODUCTION From the dualistic classification that divides endometrial cancer (EC) into two types with distinct underlying molecular profiling, histopathology and clinical behavior, arises a deeper understanding of the carcinogenesis pathways. EC treatment comprises different and multimodal therapeutic approaches, such as chemotherapy, radiation therapy or combinations of novel drugs; however,...

The standard primary treatment for advanced prostate cancer has been hormonal therapy since the 1940s. However, prostate cancer inevitably progresses to castration-resistant prostate cancer (CRPC) after a median duration of 18 months of androgen deprivation therapy. In patients with CRPC, docetaxel has been regarded as the standard treatment. However, survival advantages of docetaxel over other...

increased y-glutamyltransferase activities (three quarters of whom were hazardous drinkers), and this test is under evaluation as a tool for further investigation, treatment, and control of high alcohol consumption.26 In conclusion, commonly available laboratory markers, either individually or in combination, are not effective screening tests for detecting hazardous drinking but do identify tho...

We systematically compared the adverse effects of cancer drugs to detect event outliers across different clinical trials using a data-driven approach. Because many cancer drugs are toxic to patients, better understanding of adverse events of cancer drugs is critical for developing therapies that could minimize the toxic effects. However, due to the large variabilities of adverse events across d...

Objective To examine the effects of fertility drugs on overall riskofovariancancerusingdata froma largecohort